The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Donepezil Improves Cognition and Global Function in Alzheimer Disease<subtitle>A 15-Week, Double-blind, Placebo-Controlled Study</subtitle>
Abstract
BACKGROUND: Donepezil hydrochloride (Aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer disease. This phase 3 study was 1 of 2 pivotal trials undertaken to establish the efficacy and safety of using donepezil in patients with mild to moderately severe Alzheimer disease. OBJECTIVES: To further examine the efficacy and safety of using donepezil in the treatment of patients with mild to moderately severe Alzheimer disease. To examine the relationships between plasma donepezil concentrations, inhibition of red blood cell acetylcholinesterase activity, and clinical response. METHODS: This was a 12-week, double-blind, placebo-controlled, parallel-group trial with a 3-week single-blind washout. Outpatients at 23 centers in the United States were randomized to receive placebo, 5 mg of donepezil hydrochloride, or 10 mg of donepezil hydrochloride (5 mg/d during week 1 then 10 mg/d thereafter) administered once daily at bedtime. Primary efficacy was measured using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change including caregiver information (CIBIC plus). RESULTS: A total of 468 patients entered the study, more than 97% of whom were included in the intention-to-treat (end point) analyses. The use of donepezil produced statistically significant improvements in ADAS-cog, CIBIC plus, and Mini-Mental State Examination scores, relative to placebo. The mean drug-placebo differences, at end point, for the groups receiving 5 mg/d and 10 mg/d of donepezil hydrochloride were, respectively, 2.5 and 3.1 units for ADAS-cog (P<.001); 0.3 and 0.4 units for CIBIC plus (P< or =.008); and 1.0 and 1.3 units for Mini-Mental State Examination (P< or =.004). On the CIBIC plus scale, 32% and 38% of patients, respectively, treated with 5 mg/d and 10 mg/d of donepezil hydrochloride demonstrated clinical improvement (a score of 1, 2, or 3) compared with placebo (18%). The mean (+/-SEM) donepezil plasma concentrations at study end point were 25.9 +/- 0.7 ng/mL and 50.6 +/- 1.9 ng/mL in the groups receiving dosages of 5 mg/d and 10 mg/d, respectively. Corresponding mean (+/-SEM) percentages of inhibition of red blood cell acetylcholinesterase activity were 63.9% +/- 0.9% and 74.7% +/- 1.2% for these 2 dosages, respectively. There was a statistically significant positive correlation between plasma concentrations of donepezil and acetylcholinesterase inhibition; the EC50 (50% effect) was obtained at a concentration of 15.6 ng/mL. A plateau of inhibition (80%-90%) was reached at plasma donepezil concentrations higher than 50 ng/mL. The correlations between plasma drug concentrations and both ADAS-cog (P<.001) and CIBIC plus (P = .006) were also statistically significant, as were the correlations between red blood cell acetylcholinesterase inhibition and change in ADAS-cog (P<.001) and CIBIC plus (P = .005). The incidence of treatment-emergent adverse events with both dosages of donepezil (68%-78%) was comparable with that observed with placebo (69%). The use of 10 mg/d of donepezil hydrochloride was associated with transient mild nausea, insomnia, and diarrhea. There were no treatment-emergent clinically significant changes in vital signs or clinical laboratory test results. More important, the use of donepezil was not associated with the hepatotoxic effects observed with acridine-based cholinesterase inhibitors. CONCLUSION: Donepezil hydrochloride (5 and 10 mg) administered once daily is a well-tolerated and efficacious agent for treating the symptoms of mild to moderately severe Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Comprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,799
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718 · cited 1×
“The categorical efficacy variable, the CIBIC plus, was analyzed using the Cochran-Mantel-Haenszel test, with RIDITS as the score option.(27,28) The Cochran-Mantel-Haenszel test included adjustment for center.”
MethodSELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Self-citation
Cited by
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Oral Care Reduces Pneumonia in Older Patients in Nursing Homes
Yoneyama, T., Yoshida, M., Ohrui, T., Mukaiyama, H., Okamoto, H., Hoshiba, K., Ihara, S., Yanagisawa, S., Ariumi, S., Morita, T., et al. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50106.x · Cited by 791
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 626
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 601
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 580
Self-citationKaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190 · Cited by 515
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 503
Self-citationA Review of 12 Commonly Used Medicinal Herbs
O'Hara, M. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.6.523 · Cited by 477
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 384
Tariot, P. N., Cummings, J. L., Katz, I. R., Mintzer, J., Perdomo, C. A., Schwam, E. M., & Whalen, E. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.t01-1-49266.x · Cited by 370
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 345
Goldberg, T. E., Harvey, P. D., Wesnes, K. A., Snyder, P. J., & Schneider, L. S. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.003 · Cited by 343
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Acetylcholinesterase inhibitors in Alzheimer’s disease
McGleenon, Dynan, & Passmore (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00026.x · Cited by 317
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51306.x · Cited by 313
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Cognitive Intervention in Alzheimer Disease: A Randomized Placebo-Controlled Study
Davis, R. N., Massman, P. J., & Doody, R. S. (2001) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200101000-00001 · Cited by 300
Achieving and Maintaining Cognitive Vitality With Aging
Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., Greenough, W. T., Gold, P. E., Kramer, A. F., Kuller, L. H., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.681 · Cited by 300
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub2 · Cited by 285
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Krishnan, K. R. R., Charles, H. C., Doraiswamy, P. M., Mintzer, J., Weisler, R., Yu, X., Perdomo, C., Ieni, J. R., & Rogers, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2003 · Cited by 282
Self-citationEffects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood, K. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.589 · Cited by 279
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
Ravina, B. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 273
Sleep disorders in Alzheimer's disease and other dementias
Bliwise, D. L. (2004) · Clinical Cornerstone · doi:10.1016/s1098-3597(04)90014-2 · Cited by 272
Cholinesterase Inhibitors for Alzheimer??s Disease
Grutzendler, J., & Morris, J. C. (2001) · Drugs · doi:10.2165/00003495-200161010-00005 · Cited by 270
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
Self-citationEfficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Seltzer, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1852 · Cited by 257
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
Lopez, O. L. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.3.310 · Cited by 255
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Confusional State in Stroke: Relation to Preexisting Dementia, Patient Characteristics, and Outcome
Hénon, H., Lebert, F., Durieu, I., Godefroy, O., Lucas, C., Pasquier, F., & Leys, D. (1999) · Stroke · doi:10.1161/01.str.30.4.773 · Cited by 168
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom
Getsios, D., Blume, S., Ishak, K. J., Maclaine, G., & Hernández, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.07.001 · Cited by 144
Blackman, J., Swirski, M., Clynes, J., Harding, S., Leng, Y., & Coulthard, E. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13229 · Cited by 141
“…donepezil has been associated with vivid dreams and insomnia with higher incidences versus placebo reported in multiple studies (Burns et al., 1999; Pratt et al., 2002; Rogers et al., 1998) which alongside their common use in those with early cognitive impairment may have driven further research.”
ResultParnetti, L., Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.043 · Cited by 122
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Wilkinson, D., Stave, C., Keohane, D., & Vincenzino, O. (2004) · Journal of International Medical Research · doi:10.1177/147323000403200207 · Cited by 99
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell, A. S., Gonzales, C., Williams, J., Witte, M. M., Mohs, R. C., & Sperling, R. (2007) · Neurology · doi:10.1212/01.wnl.0000260240.46070.7c · Cited by 89
Kobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79
Traini, E., Bramanti, V., & Amenta, F. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660173 · Cited by 78
Burns, A., Gauthier, S., & Perdomo, C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1746 · Cited by 71
“…to improve significantly cognition and to stabilise and maintain or produce less than expected decline in global function and activities of daily living in double-blind, placebo-controlled studies of up to one year duration (Rogers et al., 1998a, 1998b; Mohs et al., 2001; Winblad et al., 2001).”
BackgroundSystematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
Leinonen, A., Koponen, M., & Hartikainen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124500 · Cited by 64
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Weycker, D., Taneja, C., Edelsberg, J., Haim Erder, M., Schmitt, F. A., Setyawan, J., & Oster, G. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188071 · Cited by 52
Balducci, C., Nurra, M., Pietropoli, A., Samanin, R., & Carli, M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1385-7 · Cited by 42
The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil
Yasui‐Furukori, N., Furukori, H., Kaneda, A., Kaneko, S., & Tateishi, T. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004264161 · Cited by 38
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Galvin, V. C., Arnsten, A. F. T., & Wang, M. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00067 · Cited by 25
Tariot, P. N., Braeckman, R., & Oh, C. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220530 · Cited by 24
Metadata
- Authors
- Rogers, S. L.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1998-05-11
- Volume
- 158
- Issue
- 9
- Pages
- 1021
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2055727638
- Cited by
- 773
- References
- 31
- FWCI
- 37.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.